Free Trial

Revolution Medicines Q1 2024 Earnings Report

Revolution Medicines logo
$45.11 -0.05 (-0.11%)
(As of 11:03 AM ET)

Revolution Medicines Earnings Headlines

Insiders Are Loving These 6 Stocks Right Now
URGENT: This Altcoin Opportunity Won’t Wait – Act Now
All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.
See More Revolution Medicines Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Revolution Medicines? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Revolution Medicines and other key companies, straight to your email.

About Revolution Medicines

Revolution Medicines (NASDAQ:RVMD), a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

View Revolution Medicines Profile

More Earnings Resources from MarketBeat

Upcoming Earnings